within Pharmacolibrary.Drugs.ATC.L;

model L04AC05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 45 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0032,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0024,
    k12             = 0.36,
    k21             = 0.36
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AC05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ustekinumab is a human monoclonal antibody targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), used primarily for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is approved for clinical use in many countries and is considered a biologic therapy for immune-mediated inflammatory disorders.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters for ustekinumab in adults with moderate to severe plaque psoriasis after subcutaneous administration.</p><h4>References</h4><ol><li><p>Grabowski, T, et al., &amp; Borkowski, J (2021). Ustekinumab pharmacokinetics after subcutaneous administration in swine model. <i>Journal of veterinary science</i> 22(5) e47–None. DOI:<a href=\"https://doi.org/10.4142/jvs.2021.22.e47\">10.4142/jvs.2021.22.e47</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34423596/\">https://pubmed.ncbi.nlm.nih.gov/34423596</a></p></li><li><p>Feagan, BG, et al., &amp; Rutgeerts, P (2016). Ustekinumab as Induction and Maintenance Therapy for Crohn&#x27;s Disease. <i>The New England journal of medicine</i> 375(20) 1946–1960. DOI:<a href=\"https://doi.org/10.1056/NEJMoa1602773\">10.1056/NEJMoa1602773</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27959607/\">https://pubmed.ncbi.nlm.nih.gov/27959607</a></p></li><li><p>Weber, J, &amp; Keam, SJ (2009). Ustekinumab. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 23(1) 53–61. DOI:<a href=\"https://doi.org/10.2165/00063030-200923010-00006\">10.2165/00063030-200923010-00006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19344192/\">https://pubmed.ncbi.nlm.nih.gov/19344192</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AC05;
